SCHEMBL6763103

SCHEMBL6763103

COc1ccc(NC(=O)Nc2cc(C(F)(F)F)ccc2Cl)c(O)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.61
CYP2C19 P33261 4/20 0.61
CYP1A2 P05177 3/20 0.61
CYP2D6 P10635 3/20 0.61
CHRNA7 P36544 1/20 0.61
KMT2A Q03164 4/20 0.59
MEN1 O00255 3/20 0.59
TRPV1 Q8NER1 1/20 0.55
MAPT P10636 3/20 0.54
CYP2C9 P11712 1/20 0.54
TP53 P04637 1/20 0.53
GAA P10253 1/20 0.53
HPGD P15428 2/20 0.53
ALDH1A1 P00352 2/20 0.50
MAPK1 P28482 1/20 0.50
KDM4E B2RXH2 1/20 0.50
POLB P06746 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
LMNA P02545 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6760901 0.84 EPHX2 (0.56) KMT2AMEN1TRPV1MAPTTP53
SCHEMBL6764064 0.84 P2RX1 (0.64) KMT2AMEN1MAPTGAAALDH1A1
SCHEMBL6820148 0.84 CYP1A2 (0.54) CYP3A4CYP2C19CYP1A2CYP2D6CHRNA7
SCHEMBL330643 0.82 TMPRSS4 (0.69) CYP3A4CYP2C19CYP1A2CYP2D6CHRNA7
SCHEMBL20472469 0.82 CHRNA7 (0.76) CYP3A4CYP2C19CYP1A2CHRNA7KMT2A
SCHEMBL29776952 0.82 CHRNA7 (0.76) CYP3A4CYP2C19CYP1A2CHRNA7KMT2A
SCHEMBL5613115 0.81 CYP1A2 (0.49) CYP3A4CYP2C19CYP1A2CYP2D6CHRNA7
SCHEMBL1463349 0.81 GSK3A (0.66) KMT2AMEN1TRPV1MAPTGAA
SCHEMBL5595253 0.81 CHRNA7 (0.61) CYP3A4CYP2C19CYP1A2CHRNA7KMT2A
SCHEMBL5594895 0.81 CHRNA7 (0.61) CYP3A4CYP2C19CYP1A2CHRNA7KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040063742-A1 Treatment of parkinson's disease by the combined action of a compound with neurotrophic activity and a compound enhancing the dopamine activity NEUROSEARCH A/S (DK) 2004-04-01 US claimed
US-20040063742-A1 Treatment of parkinson's disease by the combined action of a compound with neurotrophic activity and a compound enhancing the dopamine activity NEUROSEARCH A/S (DK) 2004-04-01 US disclosed